Kevin W. Tosh
About Kevin W. Tosh
Kevin W. Tosh is a Principal Scientist at Carisma Therapeutics, with extensive experience in microbiology, immunology, and cellular activation pathways. He has held various research positions at notable institutions, including Penn Medicine and Kite Pharma, and has a Doctor of Philosophy in Microbiology and Immunology from Georgetown University.
Work at Carisma Therapeutics
Kevin W. Tosh currently serves as Principal Scientist at Carisma Therapeutics, a position he has held since 2022. His role involves leading research initiatives focused on cellular therapies. Prior to this, he worked as Senior Research Scientist at Carisma Therapeutics from 2021 to 2022. His expertise in immunology and cellular activation pathways contributes to the company's mission of developing innovative treatments.
Education and Expertise
Kevin W. Tosh holds a Doctor of Philosophy in Microbiology and Immunology from Georgetown University, where he studied from 2011 to 2015. He also earned a Master of Science in Microbiology and Immunology from the same institution in 2009. His undergraduate studies include a Bachelor of Science in Biology from Lambuth University and a Bachelor of Science in Cell Biology from Union University. His expertise encompasses innate and adaptive signaling pathways, multi-color flow cytometry, and phenotypic analysis of human immune cells.
Background
Before joining Carisma Therapeutics, Kevin W. Tosh gained extensive research experience in various roles. He worked as a Postdoctoral Researcher at Penn Medicine from 2016 to 2018 and held positions at Kite Pharma as Research Scientist and Senior Research Scientist from 2019 to 2021. He also served as a Research Scientist in Immuno-Oncology at Precigen from 2018 to 2019 and as an ORISE Research Fellow at the Food & Drug Administration from 2009 to 2011.
Achievements
Kevin W. Tosh has made significant contributions to the field of immunology, including identifying unique interferon-stimulated gene signatures related to HCV treatment. He has developed a primary cell assay to study the innate immune response to Toxoplasma gondii. Additionally, he has received recognition for effectively communicating scientific findings at both local and international conferences, showcasing his ability to convey complex information clearly.